Follow-up to Eshel Hayarden: How Much of KAVA's Profit Really Reaches the Listed Issuer
KAVA already provides real demand evidence and strong project economics, but the path from that headline value to cash that is accessible to Eshel Hayarden is far narrower. Only half the project belongs to the company, surplus release is lender-controlled, and the amount already visible at the issuer is still much smaller than the project's 100% numbers.
The main article framed KAVA as the first project that starts to prove Eshel Hayarden can turn land, financing and marketing into a real operating development. This follow-up isolates the question that matters most now: how much of KAVA's profit really belongs to the listed issuer, and how much still sits at the project level, inside Diurim, or trapped in the project account.
That question matters especially here. Eshel Hayarden is a bond issuer, so the key number is not only how much project profit can be shown on paper, but when and how much of it can actually become surplus that is accessible at the issuer layer. That is where the gap sits.
The right way to read KAVA is to separate three layers. The first is the project itself on a 100% basis, where the filing shows expected revenue of NIS 581.3 million, expected gross profit of NIS 239.6 million, and expected withdrawable surplus of NIS 250.0 million including selling and financing expenses. The second layer is Diurim, the jointly owned company that holds the project together with Migido, with Eshel Hayarden owning 50%. The third layer is Eshel Hayarden itself, which only records its share in Diurim under the equity method rather than the full economics of KAVA.
That leads to the core conclusion. Even if KAVA delivers exactly as projected, not all of that value reaches Eshel Hayarden, and it certainly does not reach it now. Part belongs to the partner, part remains subject to the lender, and part first appears as accounting profit or shareholder-loan exposure inside Diurim before it can become free cash at the issuer.
KAVA already proves there is a product, not that there is cash
What has already been proven by year-end 2025 is meaningful. The project includes 246 residential units, of which 182 units are already under construction, and phase A offered 146 units for sale. By year-end, 60 contracts had been signed, so total project marketing reached 22%. On that basis, the company presents expected total revenue of NIS 581.3 million, expected costs of NIS 341.7 million, and expected total gross profit of NIS 239.6 million, implying a 41% gross margin.
That is a strong number, and it understandably draws attention. But it has to be read next to the line that is much easier to miss: as of the report date, KAVA had still not recognized revenue from its binding sale agreements, and it had not yet received advances from the project either. In plain terms, the project already proves demand and economic viability, but year-end 2025 is still not a monetization point at the recognized-revenue level.
There is another layer of precision here. Even inside the project itself, there is no single headline number that summarizes the economics cleanly. Expected gross profit stands at NIS 239.6 million, but the expected withdrawable-surplus table shows NIS 278.1 million, or NIS 250.0 million including selling and financing expenses. The gap exists because the monitor and lender framework treats land revaluation and selling and credit costs differently from the accounting gross-profit view. This is not semantics. Even before leaving the project layer, you have to decide whether you are looking at accounting gross profit or at project surplus.
The bridge from a 100% project to a 50% issuer
The right question is not simply what KAVA is worth at the project level. The right question is what survives after each transfer layer.
| Layer | Key number | What it does show | What it still does not show |
|---|---|---|---|
| KAVA on a 100% basis | Expected gross profit of NIS 239.6 million, or expected withdrawable surplus of NIS 250.0 million including selling and financing | The project's economics if execution follows the year-end 2025 assumptions | Not a number that fully belongs to Eshel Hayarden, and not cash available today |
| Eshel Hayarden look-through share | Roughly NIS 119.8 million as half the gross profit, or roughly NIS 125.0 million as half the surplus including selling and financing | An analytical approximation of Eshel Hayarden's economic share based on its 50% effective stake | Not a reported issuer number, and not something that can be pulled automatically |
| Diurim | NIS 83.9 million of revenue and NIS 9.8 million of net profit in 2025 | The annual result of the joint company that holds KAVA and other projects | Not pure KAVA profit, and not surplus already upstreamed to the issuer |
| Eshel Hayarden | NIS 4.9 million share in joint-venture profit, and NIS 18.8 million carrying value of the investment in Diurim | What has already crossed into Eshel Hayarden's own financial statements | Not proof that the profit is already accessible for debt service or distribution |
The chart below is an analytical bridge, not a reported number. Its purpose is to show how quickly a large-looking project number shrinks at the first step, even before lender restrictions and before the Diurim layer itself:
This does not mean Eshel Hayarden's share in KAVA is only NIS 125 million. It means that this is roughly the economic magnitude you can begin with on a look-through basis, and only from there do you continue subtracting what still sits in the way: lender restrictions, execution pace, cash distribution from Diurim, and timing.
Diurim's profit is not accessible surplus, and it is not necessarily KAVA profit either
This is probably the biggest source of confusion. Diurim ended 2025 with NIS 83.9 million of revenue and NIS 9.8 million of net profit. Eshel Hayarden recorded NIS 4.9 million as its share in the joint venture's profit. On a first pass, it is easy to jump to the conclusion that KAVA has already started to flow profit up to the listed issuer.
That is too shallow a reading. The same note that presents Diurim's numbers also makes clear that Diurim still holds additional projects in Migdal HaEmek. One of them received occupancy approvals during 2024, and in the other the final four apartments were sold in 2025. By contrast, KAVA's own project table states that no revenue had yet been recognized from the project and no advances had yet been received by the report date. So Diurim's 2025 profit is a result for the joint company as a whole, not evidence that KAVA itself has already been translated into recognized profit and issuer cash.
Diurim's balance sheet reinforces the same point. At the end of 2025, Diurim had NIS 149.2 million of current assets against NIS 134.6 million of current liabilities and NIS 4.5 million of non-current liabilities, leaving equity of only NIS 10.6 million. Eshel Hayarden carries its investment in Diurim at NIS 18.8 million, but that amount is composed mainly of NIS 13.4 million of loans to Diurim and only NIS 5.3 million of equity share. In other words, even what already appears at the issuer level is still, to a large extent, owner-loan exposure rather than profit that has already been released and turned into free surplus.
That gap matters. It shows that value exists in KAVA, but for now that value exists mainly at the project layer and at the joint-venture layer. The path to the issuer layer is still incomplete.
When the value may actually become accessible
For KAVA's profit to stop being mainly a project story and turn into value that is truly accessible to the issuer, four things need to happen.
First, the project has to continue moving from construction and signed sales into actual revenue recognition. As long as KAVA shows contracts but not recognized revenue, the commercial proof exists, but the accounting proof is still pending.
Second, the financing layer has to open in substance. The project financing agreement makes clear that this is a closed project account: withdrawals are allowed only for project purposes, release of funds depends on sales pace, budget, timeline, receipts and the absence of a default event, and the company is not allowed to pull money from the project account for non-project use without prior written lender approval. Beyond that, expected surplus release is scheduled only from 2027 onward.
Third, any surplus, if and when it is released, still has to move through Diurim itself. This is a joint company, not an empty conduit. Only after the partner share, and only after distributions or shareholder-loan repayments, can one talk about money that is truly accessible to Eshel Hayarden.
Fourth, downside travels together with upside. To secure the borrower's obligations, guarantees were given by Eshel Hayarden and the controlling shareholder for an aggregate 50% of total credit, while Migido provides the remaining 50%. That means Eshel Hayarden owns half the upside, but it also sits behind half of the support package.
Conclusion
KAVA deserves the attention it gets. It is no longer theoretical inventory. It has signed sales, visible execution and project economics that look strong on paper. But that is still not the same thing as profit that is accessible to Eshel Hayarden.
The number most likely to attract attention is NIS 239.6 million of expected gross profit, or NIS 250.0 million of expected withdrawable surplus including selling and financing. The number that has actually reached Eshel Hayarden's own layer so far is very different: NIS 4.9 million of share in joint-venture profit, and NIS 18.8 million of carrying value in Diurim, most of which is owner loans.
So the right reading of KAVA at the end of 2025 is this: it is a project that is beginning to prove demand and execution economics, but it has not yet proven a full transition from project profit to value that is accessible at the listed issuer. The market can be impressed by the project numbers, but the real test arrives only when KAVA moves from promised surplus to released surplus, and from joint-venture profit share to cash that can actually be seen at the Eshel Hayarden layer.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.